olaratumab

10/01/2019 - "First trial was ANNOUNCE trial which was done to confirm the efficacy of olaratumab after its dramatic success in advanced soft tissue sarcoma in a phase 2 trial. "
01/01/2018 - "Ongoing and future preclinical and translational studies, coupled with the anticipated results of a phase III trial that has completed enrolment, should provide greater insight into the efficacy and mode of action of olaratumab in soft tissue sarcomas."
12/01/2017 - "Trials of olaratumab for advanced soft tissue sarcomas were prioritized. "
10/01/2017 - "We provide an overview of the published studies to date for olaratumab and specifically the use in soft tissue sarcoma. "
10/01/2017 - "In this review, we describe some of the preclinical and early clinical data of olaratumab in sarcomas, the Phase Ib/II trial and ongoing trials with olaratumab in sarcomas."

01/01/2018 - "In vivo activity of olaratumab was assessed in preclinical mouse models of pediatric osteosarcoma and malignant rhabdoid tumor.Results"
01/01/2018 - "Olaratumab was investigated in in vitro cell proliferation and invasion assays using pediatric osteosarcoma and rhabdoid tumor cell lines. "
09/01/2019 - "The goal of the present study was to determine the efficacy of the combination of olaratumab (OLA), doxorubicin (DOX), and cisplatinum (CDDP) on osteosarcoma, which is resistant to first-line therapy, in a patient-derived orthotopic xenograft (PDOX) model. "
09/01/2019 - "The Combination of Olaratumab with Doxorubicin and Cisplatinum Regresses a Chemotherapy-Resistant Osteosarcoma in a Patient-Derived Orthotopic Xenograft Mouse Model."
01/01/2018 - ":In vitro olaratumab treatment of osteosarcoma and rhabdoid tumor cell lines reduced proliferation and inhibited invasion driven by individual platelet-derived growth factors (PDGFs) or serum. "

01/01/2019 - "Maximum benefit in OS was achieved in the upper three quartiles and a potential of early disease progression in the lower quartile of olaratumab serum exposure. "
12/01/2018 - "Patients received olaratumab 15 mg/kg on Days 1 and 8 during each 21-day cycle until disease progression. "
12/01/2018 - "Subsequent exposure-response analysis suggested that higher olaratumab exposures earlier might improve outcomes in patients at risk of early disease progression. "
01/01/2017 - "Olaratumab was continued in the olaratumab+P/C arm until disease progression. "
01/01/2017 - "Patients received olaratumab 20 mg/kg intravenously every 14 days until disease progression, death, or intolerable toxicity occurred. "

12/01/2017 - "Olaratumab, in combination with doxorubicin, represents a novel treatment strategy for advanced soft tissue sarcoma and provides a significant survival advantage for this rare disease state with limited treatment options."

01/01/2018 - "In this study, we investigated olaratumab in preclinical models of pediatric bone and soft tissue tumors.Experimental"
01/01/2018 - "In this study, we characterize the pharmacokinetics (PKs) of olaratumab in a cancer patient population. "
01/01/2017 - "Olaratumab has also been investigated in phase II trials in several other cancers. "
07/01/2014 - "This was a single-center, dose-escalation, phase I trial of olaratumab in Japanese patients with advanced/refractory solid malignancies. "
07/01/2014 - "Phase I study of olaratumab in Japanese patients with advanced solid tumors."